Reviewed by Shameer Deen, ST5 Urology Registrar
Warfarin is a narrow therapeutic index anticoagulant with one of the longest and most clinically significant drug interaction lists of any medicine in common use. Its interactions are responsible for a disproportionate share of preventable medication-related hospital admissions [1]. Despite the increasing use of direct oral anticoagulants (DOACs), warfarin remains the anticoagulant of choice in several important clinical situations — mechanical heart valves, rheumatic mitral stenosis, antiphospholipid syndrome — and clinicians must be proficient in managing its interactions.
Pharmacology: Why Warfarin Interacts with So Much
Warfarin is a racemic mixture of R- and S-enantiomers, with S-warfarin being approximately four times more pharmacologically active [2]. S-warfarin is principally metabolised by CYP2C9, while R-warfarin is metabolised by CYP1A2 and CYP3A4. Warfarin works by inhibiting vitamin K epoxide reductase (VKOR), preventing the recycling of vitamin K and thereby reducing the activity of clotting factors II, VII, IX, and X.
Its narrow therapeutic window — typically a target INR of 2.0-3.0 for most indications — means that even modest changes in warfarin metabolism produce clinically significant INR shifts. Genetic polymorphisms in CYP2C9 (affecting metabolism) and VKORC1 (affecting sensitivity) explain much of the interindividual variability in warfarin dosing [1].
Pharmacokinetic Interactions: CYP Enzyme Effects
The most clinically important warfarin interactions are pharmacokinetic, mediated through inhibition or induction of CYP2C9 [1]:
CYP2C9 Inhibitors (increase INR)
- Fluconazole — one of the most potent CYP2C9 inhibitors in clinical use. A single course can double or triple the INR. INR must be checked 2-3 days after starting and after completing fluconazole.
- Amiodarone — inhibits both CYP2C9 and CYP1A2. The interaction develops slowly (weeks) because of amiodarone's extremely long half-life but can be severe and prolonged.
- Metronidazole — significant CYP2C9 inhibition; common clinical scenario when treating a patient on warfarin for a gut or dental infection.
- Trimethoprim and co-trimoxazole — both CYP2C9 inhibition and displacement from protein binding sites.
- Some SSRIs — fluoxetine and fluvoxamine are notable CYP2C9 inhibitors; sertraline and citalopram have less potent effects but may still increase bleeding risk through platelet effects.
CYP2C9 Inducers (decrease INR)
- Rifampicin — the most potent CYP2C9 and CYP3A4 inducer in clinical use. May reduce warfarin effect by up to 90%. The interaction develops within days of starting rifampicin and reverses equally rapidly on stopping.
- Carbamazepine and phenytoin — antiepileptic enzyme inducers; may require doubling of warfarin dose.
- St John's Wort (Hypericum perforatum) — a potent inducer of CYP3A4 and P-glycoprotein; significant reduction in warfarin effect. Patients on warfarin must be warned about this herbal medicine.
Pharmacodynamic Interactions
Several drugs potentiate warfarin's anticoagulant effect without altering its metabolism [2]:
- Aspirin and NSAIDs — antiplatelet effect plus GI mucosal damage creates marked bleeding risk when combined with anticoagulation
- Heparin and DOACs — additive anticoagulant effects; rarely intentional combinations
- Broad-spectrum antibiotics — reduce gut flora synthesis of vitamin K, augmenting warfarin effect; INR check after any antibiotic course
Dietary Interactions
Vitamin K intake directly antagonises warfarin's mechanism of action. Foods rich in vitamin K (dark leafy greens — kale, spinach, broccoli) can significantly reduce INR if consumed inconsistently [1]. The key message is consistency: patients should maintain a stable, not minimal, intake of vitamin K-rich foods. Cranberry juice inhibits CYP2C9 and has been associated with INR elevation.
Practical Management Principles
Whenever a new drug is added to a warfarin regimen, check for interactions using a validated resource such as MedNext Formulary's interaction checker. If an interacting drug is unavoidable, increase the frequency of INR monitoring at initiation and after completing the course. Document the anticipated direction of the interaction so that dose adjustment can be anticipated rather than reactive. MedNext's interaction database, drawn from the MedNext Audited Proprietary Dataset, flags all clinically significant warfarin interactions with severity grading and management guidance.
References
- Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-1106.
- Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-e88S.